A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours

Madhuri Kalathur, Alberto Toso, Jingjing Chen, Ajinkya Revandkar, Claudia Danzer-Baltzer, Ilaria Guccini, Abdullah Alajati, Manuela Sarti, Sandra Pinton, Lara Brambilla, Diletta Di Mitri, Giuseppina Carbone, R. Garcia-Escudero, Alessandro Padova, Letizia Magnoni, Alessia Tarditi, Laura Maccari, Federico Malusa, Ravi Kiran Reddy Kalathur, Lorenzo A. PinnaGiorgio Cozza, Maria Ruzzene, Nicolas Delaleu, Carlo V. Catapano, Ian J. Frew, Andrea Alimonti

Research output: Contribution to journalArticle

Abstract

Enhancement of cellular senescence in tumours triggers a stable cell growth arrest and activation of an antitumour immune response that can be exploited for cancer therapy. Currently, there are only a limited number of targeted therapies that act by increasing senescence in cancers, but the majority of them are not selective and also target healthy cells. Here we developed a chemogenomic screening to identify compounds that enhance senescence in PTEN-deficient cells without affecting normal cells. By using this approach, we identified casein kinase 2 (CK2) as a pro-senescent target. Mechanistically, we show that Pten loss increases CK2 levels by activating STAT3. CK2 upregulation in Pten null tumours affects the stability of Pml, an essential regulator of senescence. However, CK2 inhibition stabilizes Pml levels enhancing senescence in Pten null tumours. Taken together, our screening strategy has identified a novel STAT3-CK2-PML network that can be targeted for pro-senescence therapy for cancer.

Original languageEnglish
Article number7227
JournalNature Communications
Volume6
DOIs
Publication statusPublished - Jun 18 2015

Fingerprint

Casein Kinase II
Tumors
therapy
Screening
tumors
screening
cancer
cells
Neoplasms
perfectly matched layers
regulators
Therapeutics
actuators
activation
Cell growth
augmentation
Cell Aging
Chemical activation
Cells
Up-Regulation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemistry(all)
  • Physics and Astronomy(all)

Cite this

Kalathur, M., Toso, A., Chen, J., Revandkar, A., Danzer-Baltzer, C., Guccini, I., ... Alimonti, A. (2015). A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. Nature Communications, 6, [7227]. https://doi.org/10.1038/ncomms8227

A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. / Kalathur, Madhuri; Toso, Alberto; Chen, Jingjing; Revandkar, Ajinkya; Danzer-Baltzer, Claudia; Guccini, Ilaria; Alajati, Abdullah; Sarti, Manuela; Pinton, Sandra; Brambilla, Lara; Di Mitri, Diletta; Carbone, Giuseppina; Garcia-Escudero, R.; Padova, Alessandro; Magnoni, Letizia; Tarditi, Alessia; Maccari, Laura; Malusa, Federico; Kalathur, Ravi Kiran Reddy; Pinna, Lorenzo A.; Cozza, Giorgio; Ruzzene, Maria; Delaleu, Nicolas; Catapano, Carlo V.; Frew, Ian J.; Alimonti, Andrea.

In: Nature Communications, Vol. 6, 7227, 18.06.2015.

Research output: Contribution to journalArticle

Kalathur, M, Toso, A, Chen, J, Revandkar, A, Danzer-Baltzer, C, Guccini, I, Alajati, A, Sarti, M, Pinton, S, Brambilla, L, Di Mitri, D, Carbone, G, Garcia-Escudero, R, Padova, A, Magnoni, L, Tarditi, A, Maccari, L, Malusa, F, Kalathur, RKR, Pinna, LA, Cozza, G, Ruzzene, M, Delaleu, N, Catapano, CV, Frew, IJ & Alimonti, A 2015, 'A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours', Nature Communications, vol. 6, 7227. https://doi.org/10.1038/ncomms8227
Kalathur, Madhuri ; Toso, Alberto ; Chen, Jingjing ; Revandkar, Ajinkya ; Danzer-Baltzer, Claudia ; Guccini, Ilaria ; Alajati, Abdullah ; Sarti, Manuela ; Pinton, Sandra ; Brambilla, Lara ; Di Mitri, Diletta ; Carbone, Giuseppina ; Garcia-Escudero, R. ; Padova, Alessandro ; Magnoni, Letizia ; Tarditi, Alessia ; Maccari, Laura ; Malusa, Federico ; Kalathur, Ravi Kiran Reddy ; Pinna, Lorenzo A. ; Cozza, Giorgio ; Ruzzene, Maria ; Delaleu, Nicolas ; Catapano, Carlo V. ; Frew, Ian J. ; Alimonti, Andrea. / A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. In: Nature Communications. 2015 ; Vol. 6.
@article{665d2a8573c64436b04731d7fd1b8eaf,
title = "A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours",
abstract = "Enhancement of cellular senescence in tumours triggers a stable cell growth arrest and activation of an antitumour immune response that can be exploited for cancer therapy. Currently, there are only a limited number of targeted therapies that act by increasing senescence in cancers, but the majority of them are not selective and also target healthy cells. Here we developed a chemogenomic screening to identify compounds that enhance senescence in PTEN-deficient cells without affecting normal cells. By using this approach, we identified casein kinase 2 (CK2) as a pro-senescent target. Mechanistically, we show that Pten loss increases CK2 levels by activating STAT3. CK2 upregulation in Pten null tumours affects the stability of Pml, an essential regulator of senescence. However, CK2 inhibition stabilizes Pml levels enhancing senescence in Pten null tumours. Taken together, our screening strategy has identified a novel STAT3-CK2-PML network that can be targeted for pro-senescence therapy for cancer.",
author = "Madhuri Kalathur and Alberto Toso and Jingjing Chen and Ajinkya Revandkar and Claudia Danzer-Baltzer and Ilaria Guccini and Abdullah Alajati and Manuela Sarti and Sandra Pinton and Lara Brambilla and {Di Mitri}, Diletta and Giuseppina Carbone and R. Garcia-Escudero and Alessandro Padova and Letizia Magnoni and Alessia Tarditi and Laura Maccari and Federico Malusa and Kalathur, {Ravi Kiran Reddy} and Pinna, {Lorenzo A.} and Giorgio Cozza and Maria Ruzzene and Nicolas Delaleu and Catapano, {Carlo V.} and Frew, {Ian J.} and Andrea Alimonti",
year = "2015",
month = "6",
day = "18",
doi = "10.1038/ncomms8227",
language = "English",
volume = "6",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "NLM (Medline)",

}

TY - JOUR

T1 - A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours

AU - Kalathur, Madhuri

AU - Toso, Alberto

AU - Chen, Jingjing

AU - Revandkar, Ajinkya

AU - Danzer-Baltzer, Claudia

AU - Guccini, Ilaria

AU - Alajati, Abdullah

AU - Sarti, Manuela

AU - Pinton, Sandra

AU - Brambilla, Lara

AU - Di Mitri, Diletta

AU - Carbone, Giuseppina

AU - Garcia-Escudero, R.

AU - Padova, Alessandro

AU - Magnoni, Letizia

AU - Tarditi, Alessia

AU - Maccari, Laura

AU - Malusa, Federico

AU - Kalathur, Ravi Kiran Reddy

AU - Pinna, Lorenzo A.

AU - Cozza, Giorgio

AU - Ruzzene, Maria

AU - Delaleu, Nicolas

AU - Catapano, Carlo V.

AU - Frew, Ian J.

AU - Alimonti, Andrea

PY - 2015/6/18

Y1 - 2015/6/18

N2 - Enhancement of cellular senescence in tumours triggers a stable cell growth arrest and activation of an antitumour immune response that can be exploited for cancer therapy. Currently, there are only a limited number of targeted therapies that act by increasing senescence in cancers, but the majority of them are not selective and also target healthy cells. Here we developed a chemogenomic screening to identify compounds that enhance senescence in PTEN-deficient cells without affecting normal cells. By using this approach, we identified casein kinase 2 (CK2) as a pro-senescent target. Mechanistically, we show that Pten loss increases CK2 levels by activating STAT3. CK2 upregulation in Pten null tumours affects the stability of Pml, an essential regulator of senescence. However, CK2 inhibition stabilizes Pml levels enhancing senescence in Pten null tumours. Taken together, our screening strategy has identified a novel STAT3-CK2-PML network that can be targeted for pro-senescence therapy for cancer.

AB - Enhancement of cellular senescence in tumours triggers a stable cell growth arrest and activation of an antitumour immune response that can be exploited for cancer therapy. Currently, there are only a limited number of targeted therapies that act by increasing senescence in cancers, but the majority of them are not selective and also target healthy cells. Here we developed a chemogenomic screening to identify compounds that enhance senescence in PTEN-deficient cells without affecting normal cells. By using this approach, we identified casein kinase 2 (CK2) as a pro-senescent target. Mechanistically, we show that Pten loss increases CK2 levels by activating STAT3. CK2 upregulation in Pten null tumours affects the stability of Pml, an essential regulator of senescence. However, CK2 inhibition stabilizes Pml levels enhancing senescence in Pten null tumours. Taken together, our screening strategy has identified a novel STAT3-CK2-PML network that can be targeted for pro-senescence therapy for cancer.

UR - http://www.scopus.com/inward/record.url?scp=84934894797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934894797&partnerID=8YFLogxK

U2 - 10.1038/ncomms8227

DO - 10.1038/ncomms8227

M3 - Article

C2 - 26085373

AN - SCOPUS:84934894797

VL - 6

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 7227

ER -